The estimated Net Worth of Jens Holstein is at least $1.25 millió dollars as of 7 August 2024. Jens Holstein owns over 5,000 units of Veracyte Inc stock worth over $845,261 and over the last 4 years Jens sold VCYT stock worth over $409,374.
Jens has made over 4 trades of the Veracyte Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Jens sold 5,000 units of VCYT stock worth $145,000 on 7 August 2024.
The largest trade Jens's ever made was selling 8,720 units of Veracyte Inc stock on 14 June 2022 worth over $141,874. On average, Jens trades about 2,302 units every 129 days since 2020. As of 7 August 2024 Jens still owns at least 27,878 units of Veracyte Inc stock.
You can see the complete history of Jens Holstein stock trades at the bottom of the page.
Jens's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Veracyte Inc have traded over $201,983,044 worth of Veracyte Inc stock and bought 75,122 units worth $1,149,322 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Nicole Vitullo és Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of $804,905. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth $163,165.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Veracyte Inc executives and other stock owners filed with the SEC include: